US FDA approved Medtronic PLC's CoreValve Evolut transcatheter aortic to treat patients at intermediate risk for open-heart surgery just four months after the company filed the pre-market approval supplement for the expanded indication, the company announced July 10.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?